BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

329 related articles for article (PubMed ID: 17400422)

  • 1. Hepatic artery infusion of high-dose melphalan at reduced flow during isolated hepatic perfusion for the treatment of colorectal metastases confined to the liver: a clinical and pharmacologic evaluation.
    van Iersel LB; Verlaan MR; Vahrmeijer AL; van Persijn van Meerten EL; Tijl FG; Sparidans RW; Gelderblom H; Kuppen PJ; Tollenaar RA; van de Velde CJ
    Eur J Surg Oncol; 2007 Sep; 33(7):874-81. PubMed ID: 17400422
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increased local cytostatic drug exposure by isolated hepatic perfusion: a phase I clinical and pharmacologic evaluation of treatment with high dose melphalan in patients with colorectal cancer confined to the liver.
    Vahrmeijer AL; van Dierendonck JH; Keizer HJ; Beijnen JH; Tollenaar RA; Pijl ME; Marinelli A; Kuppen PJ; van Bockel JH; Mulder GJ; van de Velde CJ
    Br J Cancer; 2000 May; 82(9):1539-46. PubMed ID: 10789721
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Isolated hepatic perfusion with high-dose melphalan for the treatment of colorectal metastasis confined to the liver.
    Rothbarth J; Pijl ME; Vahrmeijer AL; Hartgrink HH; Tijl FG; Kuppen PJ; Tollenaar RA; van de Velde CJ
    Br J Surg; 2003 Nov; 90(11):1391-7. PubMed ID: 14598420
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Isolated hypoxic hepatic perfusion with orthograde or retrograde flow in patients with irresectable liver metastases using percutaneous balloon catheter techniques: a phase I and II study.
    van Etten B; Brunstein F; van IJken MG; Marinelli AW; Verhoef C; van der Sijp JR; Guetens G; de Boeck G; de Bruijn EA; de Wilt JH; Eggermont AM
    Ann Surg Oncol; 2004 Jun; 11(6):598-605. PubMed ID: 15172933
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Repetitive chemoembolization with melphalan plus intra-arterial immuno-chemotherapy within 5-fluorouracil and granulocyte-macrophage colony-stimulating factor (GM-CSF) as effective first- and second-line treatment of disseminated colorectal liver metastases.
    Müller H; Nakchbandi V; Chatzisavvidis I; von Voigt C
    Hepatogastroenterology; 2003; 50(54):1919-26. PubMed ID: 14696433
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase I-II study of isolated hepatic perfusion using melphalan with or without tumor necrosis factor for patients with ocular melanoma metastatic to liver.
    Alexander HR; Libutti SK; Bartlett DL; Puhlmann M; Fraker DL; Bachenheimer LC
    Clin Cancer Res; 2000 Aug; 6(8):3062-70. PubMed ID: 10955785
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hyperthermic isolated hepatic perfusion using melphalan for patients with ocular melanoma metastatic to liver.
    Alexander HR; Libutti SK; Pingpank JF; Steinberg SM; Bartlett DL; Helsabeck C; Beresneva T
    Clin Cancer Res; 2003 Dec; 9(17):6343-9. PubMed ID: 14695133
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hepatic vascular isolation and perfusion for patients with progressive unresectable liver metastases from colorectal carcinoma refractory to previous systemic and regional chemotherapy.
    Alexander HR; Libutti SK; Bartlett DL; Pingpank JF; Kranda K; Helsabeck C; Beresnev T
    Cancer; 2002 Aug; 95(4):730-6. PubMed ID: 12209715
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reduced liver uptake of arterially infused melphalan during retrograde rat liver perfusion with unaffected liver tumor uptake.
    Rothbarth J; Sparidans RW; Beijnen JH; Schultze-Kool LJ; Putter H; van de Velde CJ; Mulder GJ
    J Pharmacol Exp Ther; 2002 Nov; 303(2):736-40. PubMed ID: 12388659
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Isolated hepatic perfusion with high-dose melphalan results in immediate alterations in tumor gene expression in patients with metastatic ocular melanoma.
    Varghese S; Xu H; Bartlett D; Hughes M; Pingpank JF; Beresnev T; Alexander HR
    Ann Surg Oncol; 2010 Jul; 17(7):1870-7. PubMed ID: 20221901
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase I study of hyperthermic isolated hepatic perfusion with oxaliplatin in the treatment of unresectable liver metastases from colorectal cancer.
    Zeh HJ; Brown CK; Holtzman MP; Egorin MJ; Holleran JL; Potter DM; Bartlett DL
    Ann Surg Oncol; 2009 Feb; 16(2):385-94. PubMed ID: 19034580
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Isolated hepatic perfusion for liver metastases of malignant melanoma.
    Rizell M; Mattson J; Cahlin C; Hafström L; Lindner P; Olausson M
    Melanoma Res; 2008 Apr; 18(2):120-6. PubMed ID: 18337648
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Melphalan antitumor efficacy and hepatotoxicity: the effect of variable infusion duration in the hepatic artery.
    Rothbarth J; Woutersen RA; Sparidans RW; van de Velde CJ; Mulder GJ
    J Pharmacol Exp Ther; 2003 Jun; 305(3):1098-103. PubMed ID: 12606622
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Isolated hypoxic hepatic perfusion with melphalan in patients with irresectable ocular melanoma metastases.
    van Etten B; de Wilt JH; Brunstein F; Eggermont AM; Verhoef C
    Eur J Surg Oncol; 2009 May; 35(5):539-45. PubMed ID: 18760560
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Isolated hepatic perfusion for unresectable hepatic metastases from colorectal cancer.
    Bartlett DL; Libutti SK; Figg WD; Fraker DL; Alexander HR
    Surgery; 2001 Feb; 129(2):176-87. PubMed ID: 11174711
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Isolated hepatic perfusion for the treatment of colorectal metastases confined to the liver: recent trends and perspectives.
    Rothbarth J; Tollenaar RA; Schellens JH; Nortier JW; Kool LJ; Kuppen PJ; Mulder GJ; van de Velde CJ
    Eur J Cancer; 2004 Aug; 40(12):1812-24. PubMed ID: 15288282
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Laparoscopic placement of hepatic artery infusion pumps: technical considerations and early results.
    Cheng J; Hong D; Zhu G; Swanstrom LL; Hansen PD
    Ann Surg Oncol; 2004 Jun; 11(6):589-97. PubMed ID: 15150068
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Isolated hepatic perfusion for the treatment of patients with advanced liver metastases from pancreatic and gastrointestinal neuroendocrine neoplasms.
    Grover AC; Libutti SK; Pingpank JF; Helsabeck C; Beresnev T; Alexander HR
    Surgery; 2004 Dec; 136(6):1176-82. PubMed ID: 15657573
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Isolated hepatic perfusion with oxaliplatin combined with 100 mg melphalan in patients with metastases confined to the liver: A phase I study.
    van Iersel LB; de Leede EM; Vahrmeijer AL; Tijl FG; den Hartigh J; Kuppen PJ; Hartgrink HH; Gelderblom H; Nortier JW; Tollenaar RA; van de Velde CJ
    Eur J Surg Oncol; 2014 Nov; 40(11):1557-63. PubMed ID: 25125340
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synergistic antitumor effects of histamine plus melphalan in isolated hepatic perfusion for liver metastases.
    Brunstein F; Eggermont AM; de Wiel-Ambagtsheer Ga; van Tiel ST; Rens J; ten Hagen TL
    Ann Surg Oncol; 2007 Feb; 14(2):795-801. PubMed ID: 17096052
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.